Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2388578 | 0.98 | TLR7 (0.67) | TLR7IL6 | |
| SCHEMBL2388747 | 0.96 | TLR7 (0.69) | TLR7IL6 | |
| SCHEMBL731555 | 0.92 | TLR7 (0.63) | TLR7IL6 | |
| SCHEMBL2388529 | 0.89 | TLR7 (0.65) | TLR7 | |
| SCHEMBL2389359 | 0.88 | TLR7 (0.66) | TLR7IL6 | |
| SCHEMBL4464900 | 0.88 | TLR7 (0.66) | TLR7IL6 | |
| SCHEMBL1344409 | 0.86 | TLR7 (0.73) | TLR7IL6 | |
| SCHEMBL2388748 | 0.86 | TLR7 (0.65) | TLR7IL6 | |
| SCHEMBL2388884 | 0.86 | TLR7 (0.61) | TLR7 | |
| SCHEMBL5518125 | 0.85 | TLR7 (0.65) | TLR7IL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1728793-B1 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2016-02-03 | — | — | EP | claimed |
| US-8138172-B2 | 8-oxoadenine derivatives acting as modulators of TLR7 | ASTRAZENECA AB (SE) | 2012-03-20 | — | — | US | disclosed |
| US-8012964-B2 | 9-substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20100240623-A1 | 8-OXOADENINE DERIVATIVES ACTING AS MODULATORS OF TLR7 | ASTRAZENECA AB (SE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240623-A1 | 8-OXOADENINE DERIVATIVES ACTING AS MODULATORS OF TLR7 | TLR7, TLR8, TLR9 | TLR7 1/4885IL6 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.